Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Invesco Pharmaceuticals ETF (NY:PJP)

80.79 +0.70 (+0.87%)
Streaming Delayed Price Updated: 11:25 AM EDT, Jun 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Invesco Pharmaceuticals ETF

FDA Aims To Reduce Drug Application Review Time With New Voucher Program
The FDA Commissioner will issue vouchers that drug developers may redeem to participate in a program that will shorten its review time from about 10-12 months to 1-2 months after the company’s final... 
Via Stocktwits
Exposures Product Safety
Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion
Trump signed an executive order to lower drug prices, which could hit pharmacy benefit managers (PBMs) hard. PBMs have come under scrutiny for opaque pricing practices. Mark Cuban calls PBMs a racket. 
Via Benzinga
Topics Government
Exposures Political
Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency'
Trump vows to slash drug prices with new executive order, potentially dropping them by 30-80%. 
Via Benzinga
Topics Government
Exposures Political
Sandoz CEO Richard Saynor Slams Proposal For Europe-Wide List Price For New Medicines, Says Report
Saynor told Reuters that the proposal, put forth by Novartis and Sanofi in a letter to the Financial Times on Wednesday, overlooks the structural drivers of high drug prices in the United States and... 
Via Stocktwits
Topics Government Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Trump Administration Considers Lowering US Drug Prices To International Levels: Report
The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations. 
Via Benzinga
Topics Government
Exposures Political
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs. 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
FDA Commissioner Califf Candid on Trump's Impact: 'We Just Don't Know What's Going to Happen'
FDA Chief Robert Califf reflects on potential changes as Trump's re-election looms, expressing disappointment and highlighting uncertainty within the agency. 
Via Benzinga
Topics Government
Exposures Political Product Safety
FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch
The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer outbreak. 
Via Benzinga
Topics ETFs
Exposures COVID-19 Product Safety
COVID Activity Is Elevated Across 26 States In Summer Surge, Biden Remains In Isolation: 3 Vaccine Stocks To Watch
Over half of US states have high levels of Covid-19 in wastewater as President Biden isolates with virus. New vaccines expected by Sept. 
Via Benzinga
Exposures COVID-19
Purdue Pharma Bankruptcy Plan Rejected by Supreme Court, Billionaire Sacklers to Face Lawsuits
The Supreme Court has rejected Purdue Pharma's bankruptcy plan, exposing the Sackler family to lawsuits over their role in the opioid crisis. This decision impacts victims, state and local governments,... 
Via Benzinga
Topics Bankruptcy Lawsuit
Exposures Financial Legal
A Look At Pharma ETFs Post Q1 Earnings
Pharma ETFs have delivered mixed performances over the past month. 
Via Talk Markets
Topics ETFs
A Look At Pharma ETFs After Q4 Earnings
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. 
Via Talk Markets
Topics ETFs
Government-granted Patent Monopolies Are Not The Free Market
Our system for developing new drugs is a disaster. While we can point to great successes, they come at enormous cost. We will spend over $600B this year on prescription and non-prescription drugs -... 
Via Talk Markets
Topics Intellectual Property
Exposures Intellectual Property
Time For Gilead Sciences-Heavy ETFs?
Gilead Sciences has underperformed the broader market this year by a hefty margin. 
Via Talk Markets
Pharma ETFs in Focus Post Q2 Earnings
Second-quarter earnings for the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 30.7% on 5% revenue growth. 
Via Talk Markets
Topics ETFs
Want to Invest in Pharmaceutical Stocks but Don't Know How? Try This ETF.
Simplify your exposure to an ever-changing prescription drug market with this rules-based fund. 
Via The Motley Fool
Pharma ETFs Gain Post Q1 Earnings
Pharma ETFs have been in the green over the past month. 
Via Talk Markets
A Look At Pharma ETFs Post Q4 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month. 
Via Talk Markets
Pharma ETFs In Focus Post Q3 Earnings
Many industry bigwigs reported solid results with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month. 
Via Talk Markets
Wave of Solid Q3 Earnings Push Pharma ETFs Higher
The slew of Q3 results has led to smooth trading in pharma ETFs over the past month. 
Via Talk Markets
Will Pfizer ETFs Soar on FDA's COVID-19 Vaccine Booster Approval?
Investors have one more reason to cheer the COVID-19 vaccine update as the FDA has approved emergency use of a booster dose of the Pfizer Inc. and BioNTech SE COVID-19 vaccine. 
Via Talk Markets
Exposures COVID-19 Product Safety
3 Dividend-Paying Pharmaceutical Stocks to Buy This Summer
The pharmaceutical industry has benefited from much investor attention amid the COVID-19 pandemic. 
Via Talk Markets
Exposures COVID-19
3 Cheap Pharmaceutical Stocks to Grab Now
The pharmaceutical industry has been the beneficiary of significant investor attention amid the COVID-19 pandemic as society turned to its products to fight the coronavirus. 
Via Talk Markets
Exposures COVID-19
Pharma ETFs in Focus Post Q1 Earnings
The slew of Q1 results has led to mixed trading in pharma ETFs over the past month. Here are those in detail. 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.